Genelux Corporation Common Stock (GNLX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.53 (+0.00%), Market cap $0.13B, 52-week low–high $2.30 ~ $8.24.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China,
Financial statements, price targets, institutional (13F) holdings and related news for Genelux Corporation Common Stock are updated in real time on BlackAll Trade.
Genelux Corporation Common Stock trades at $2.53 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Genelux Corporation Common Stock has a market cap of about $0.13B.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor type